Elsisi Gihan Hamdy, El-Attar Mariam Mohamed, Ismaeil Shaimaa Mohamed, El-Shater Mohamed El-Saeed, Kirollos Mary G, Sedrak Amal S, Morad Hany, Abdel-Mohsen Heba, Abdel-Aziz Mohamed, Magdy Mohamed, Loutfy Osama
HTA Office, LLC, Cairo, Egypt.
School of Economics, American University, Cairo, Egypt.
Glob J Qual Saf Healthc. 2023 Jun 13;6(2):33-41. doi: 10.36401/JQSH-22-20. eCollection 2023 May.
The main objective of this study was to assess the cost of prostate cancer over a 1-year period from a societal perspective.
We constructed a cost-of-illness model to assess the cost of different health states of prostate cancer, metastatic or nonmetastatic, among Egyptian men. Population data and clinical parameters were extracted from the published literature. We relied on different clinical trials to extract clinical data. We considered all direct medical costs, including the costs of treatment and required monitoring, in addition to the indirect costs. The unit costs were captured from Nasr City Cancer Center and Egyptian Authority for Unified Procurement, Medical Supply, and Management of Medical Technology, and resource utilization were collected from clinical trials and validated by the Expert Panel. One-way sensitivity analysis was conducted to ensure model robustness.
The number of targeted patients with nonmetastatic hormone-sensitive prostate cancer, hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer was 215,207, 263,032, and 116,732, respectively. The total costs, in Egyptian pounds (EGP) and US dollars (USD), for the targeted patients, including drug costs and nondrug costs over a time horizon of 1 year, were EGP 41.44 billion (USD 9.010 billion) for localized prostate cancer; for metastatic prostate cancer, they doubled to EGP 85.14 billion (USD 18.510 billion), which reflects a huge burden on the Egyptian healthcare system. The drug costs for localized and metastatic prostate cancer are EGP 41,155,038,137 (USD 8.946 billion) and EGP 81,384,796,471 (USD 17.692 billion), respectively. A significant difference in nondrug costs between localized and metastatic prostate cancer was demonstrated. Nondrug costs were estimated at EGP 293,187,203 (USD 0.063 billion) for localized prostate cancer and EGP 3,762,286,092 (USD 0.817 billion) for metastatic prostate cancer. This significant difference in nondrug costs highlights the importance of early treatment due to the increased costs of progression and the burden of follow-up and productivity loss associated with metastatic prostate cancer.
Metastatic prostate cancer has a huge economic burden on the Egyptian healthcare system compared with localized prostate cancer owing to the increased costs of progression, follow-up, and productivity loss. This highlights the necessity of early treatment of these patients to save costs and lighten the burden of the disease on the patient, society, and economy.
本研究的主要目的是从社会角度评估前列腺癌一年期间的成本。
我们构建了一个疾病成本模型，以评估埃及男性中前列腺癌不同健康状态（转移性或非转移性）的成本。从已发表的文献中提取人口数据和临床参数。我们依靠不同的临床试验来提取临床数据。除间接成本外，我们考虑了所有直接医疗成本，包括治疗成本和所需的监测成本。单位成本取自纳斯尔城癌症中心以及埃及统一采购、医疗供应和医疗技术管理局，资源利用情况从临床试验中收集并经专家小组验证。进行了单向敏感性分析以确保模型的稳健性。
非转移性激素敏感性前列腺癌、激素敏感性前列腺癌和转移性去势抵抗性前列腺癌的目标患者数量分别为215,207、263,032和116,732。目标患者的总成本，以埃及镑（EGP）和美元（USD）计，包括1年时间范围内的药物成本和非药物成本，局限性前列腺癌为414.4亿埃及镑（90.10亿美元）；转移性前列腺癌的成本翻了一番，达到851.4亿埃及镑（185.10亿美元），这反映了埃及医疗系统的巨大负担。局限性和转移性前列腺癌的药物成本分别为41,155,038,137埃及镑（89.46亿美元）和81,384,796,471埃及镑（176.92亿美元）。局限性和转移性前列腺癌的非药物成本存在显著差异。局限性前列腺癌非药物成本估计为293,1-eight-seven,203埃及镑（0.63亿美元），转移性前列腺癌为3,762,286,092埃及镑（8.17亿美元）。非药物成本的这一显著差异凸显了早期治疗的重要性，因为疾病进展成本增加以及与转移性前列腺癌相关的随访负担和生产力损失。
与局限性前列腺癌相比，转移性前列腺癌给埃及医疗系统带来了巨大的经济负担，原因是疾病进展、随访和生产力损失的成本增加。这凸显了对这些患者进行早期治疗以节省成本并减轻疾病对患者、社会和经济负担的必要性。
